13 results about "Viral Receptor" patented technology

The present application relates to antibodies against poliovirus receptor (PVR) and uses thereof. The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus receptor (PVR). The antibodies can be used to treat tumors or cancers.

Manoparticies that display clade 1a, clade 1b, and clade 3 sarbecovirus receptor-binding domains and compositions thereof are provided, together with pharmaceutical compositions thereof and methods for using the nanoparticles and compositions to treat or limit Sarbecovirus infection.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.

The present invention relates to the application of snake venom polypeptide Hc-CATH in the preparation of drugs for preventing and treating Zika virus infection. The present invention takes the cathelicidin family antimicrobial peptide Hc-CATH derived from the venom gland of blue ring sea snake as the research object, and intends to clarify the role and molecular mechanism of Hc-CATH in ZIKV infection. The research of the present invention found that Hc-CATH can significantly inhibit the infection of ZIKV in vitro and in vivo, and has both preventive and therapeutic effects. The results show that Hc-CATH can directly act on ZIKV, destroy the viral envelope, induce the leakage of the viral genome, and thus inactivate viral particles; Hc-CATH can also reduce the protein level of the host cell viral receptor AXL, reducing the susceptibility of host cells to Zika virus. Combined with the small molecular weight and simple structure of the antimicrobial peptide Hc-CATH, it has broad development and application prospects.

Disclosed herein are broad-spectrum Coronavirus entry inhibitor compounds and methods of use thereof. Methods disclosed herein include inhibiting Coronavirus infection, treating a Coronavirus infection, and treating a subject at risk of contracting a Coronavirus infection. The compounds described herein target entry of Coronaviruses downstream of binding of the viral receptor.

Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CD112, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

According to the invention, lentivirus is taken as a carrier, a virus receptor DC-SIGN gene can be integrated into an ARH77 cell genome, and an ARH77 cell line for long-time stable overexpression of the DC-SIGN gene is constructed. Compared with RPMI8266 cells, the growth condition of the cells transfected by the lentivirus has the advantages that the ARH77 cells can normally grow, the RPMI8266 cells are increased, cracked and broken, the growth speed is obviously reduced, and the cell state is not improved along with the prolonging of the culture time. More importantly, the SFTSV infects ARH77 cells expressing DC-SIGN protein, the virus titer is obviously increased, and cell transcriptome level gene expression is obviously changed. Therefore, the ARH77 cell model derived from the SFTSV infected B cells is successfully constructed.

The present application relates to the field of biomedical technology and discloses a method for culturing human metapneumovirus, comprising the following steps: preparing a culture medium and placing it in a culture bottle: the culture medium comprising: DMEM culture medium, glucose, sodium bicarbonate, HEPES buffer, chondroitin sulfate, hyaluronic acid; selecting host cells; preparing a culture fluid comprising: L-glutamine, bovine serum albumin, antibiotics, and N-acetylcysteine; and inoculating human metapneumovirus into the culture medium for adsorption and infection. The present invention adds chondroitin sulfate and hyaluronic acid to the culture medium, utilizing chondroitin sulfate and hyaluronic acid to bind to glycosaminoglycans on the surface of host cells to form a complex, thereby increasing the interaction sites between the virus and the host cells, thereby enhancing the expression of viral receptors on the surface of the host cells, optimizing the cell membrane environment, thereby improving the attachment and entry efficiency of hMPV and significantly promoting the rapid proliferation of the virus.

This invention belongs to the field of biomedical engineering technology, specifically relating to the construction and application of a screening model for influenza virus receptor binding inhibitors. Addressing the problem of influenza virus hemagglutinin (HA) being prone to mutation and having multiple subtypes, making it difficult to screen for broad-spectrum inhibitors, this invention replaces HA with elderberry lectin (SNA), which specifically recognizes α-2,6-sialic acid. Using MDCK cells overexpressing α-2,6-sialic acid, a fluorescently labeled high-throughput screening model is constructed by labeling SNA with fluorescein isothiocyanate (FITC). The relative fluorescence units (RFU) of the system are detected using a multifunctional enzyme-linked immunosorbent assay (ELISA) reader. Active compounds inhibit the binding of SNA to cell surface receptors, resulting in a lower RFU value, while inactive compounds show a higher RFU value. This invention provides key technical support for the development of novel inhibitors targeting influenza virus receptor binding.

The invention relates to the technical field of biological medicines, in particular to application of an RIG-I inducer in preparation of a medicine for treating DNA demethylation medicine resistance acute myelogenous leukemia. The invention finds that although ERV dsRNA overload occurs in HMA drug-resistant cells, the viral receptor RIG-I down-regulation results in a drug-resistant mechanism that cannot trigger an IFN anti-tumor pathway, and the HMA drug-resistant mechanism based on viral receptor abnormality is a brand-new and never reported HMA drug-resistant mechanism. ATRA and TAM which can efficiently and specifically kill HMA drug-resistant AML cells are found, ATRA and TAM can specifically kill HMA drug-resistant AML, the killing effect on the drug-resistant AML cells is 4099 times and 28036 times of the killing effect on parent cells respectively, IC50 of TAM on the drug-resistant cells reaches the amazing pmol level, and the results show that ATRA and TAM have huge potential for treating HMA drug-resistant patients.

The invention provides a tissue targeting nano antibody and application thereof, and relates to the technical field of biological medicine and gene therapy. Membrane proteins (including an L-type calcium ion channel protein alpha2delta subunit CACNA2D1, a sodium ion channel protein alpha subunit SCN5A, a vascular epicardial substance BVES, a coxsackie virus adenovirus receptor CAR and the like) highly expressed in the heart and skeletal muscle are selected as targets, and a nano antibody synthesis library is used for screening. A series of nano antibodies with tissue targeting are successfully obtained by means of high-throughput sequencing, streaming and the like. The nano antibodies not only can be combined with target spots with high affinity, but also can effectively load and deliver proteins or nucleic acids, so that the enrichment amount and the treatment efficiency of the drugs in target tissues are remarkably improved, and a basis is provided for developing an efficient and safe DMD precise treatment scheme.